Androgenic condition and statins: contradictions in modern literature

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

Pathological age-related involution of the male reproductive system is characterized by combined clinical manifestations, which are designated by the terms age-related androgen deficiency syndrome, andropause, and male menopause. In modern foreign literature, the term “late hypogonadism” is more often used; in domestic literature, “age-related androgen deficiency” is utilized. The problem of late hypogonadism has gone beyond the scope of endocrinology and sexopathology. Currently, it has acquired an interdisciplinary character and gained attention from gerontologists, cardiologists, diabetologists, andrologists, and other specialists. The medical and social significance of age-related androgen deficiency syndrome is determined by the fact that it worsens the quality of life and is a risk factor for death, primarily from cardiovascular diseases. The review article presents modern ideas regarding the effect of statins on the androgen status of men with cardiac pathology and hypercholesterolemia.

作者简介

Arsen Osipov

Stavropol Regional Clinical Consulting and Diagnostic Center

编辑信件的主要联系方式.
Email: 475888@ro.ru
ORCID iD: 0009-0003-1226-373X

MD

俄罗斯联邦, Stavropol

Tatiana Derevyanko

Stavropol State Medical University

Email: uro-dep@yandex.ru
ORCID iD: 0000-0003-1659-319X
SPIN 代码: 4095-3653

MD, Dr. Sci. (Medicine), Professor

俄罗斯联邦, Stavropol

Nadezhda Agranovich

Stavropol State Medical University

Email: nagranovich@mail.ru
ORCID iD: 0000-0002-3717-7091
SPIN 代码: 8751-8613

MD, Dr. Sci. (Medicine), Professor

俄罗斯联邦, Stavropol

Roman Frantsev

Stavropol State Medical University; City Clinical Hospital of Emergency Medical Care

Email: francuz26@mail.ru
ORCID iD: 0009-0000-8893-7938
SPIN 代码: 9050-5976

MD, Cand. Sci. (Medicine)

俄罗斯联邦, Stavropol; Stavropol

Gayane Babasheva

Stavropol State Medical University

Email: babasheva.gayana@yandex.ru
ORCID iD: 0009-0005-8825-0163
SPIN 代码: 6831-5890

MD, Cand. Sci. (Medicine)

俄罗斯联邦, Stavropol

Olga Aleksandrova

Stavropol State Medical University

Email: aleksandrovaolga26@mail.ru
ORCID iD: 0009-0003-2639-2401
SPIN 代码: 5745-3207

MD

俄罗斯联邦, Stavropol

参考

  1. Barbarash OL, Davidovich IM, Pomeshkina SA, Marenin SN. Erectile dysfunction in young and middle-aged men with arterial hypertension and ischaemic heart disease. Kemerovo: Kuzbassvuzizdat; 2015. 142 p. (In Russ.)
  2. Muraleedharan V, Jones TH. Testosterone and mortality. Clin Endocrinol (Oxf). 2014;81(4):477–487. doi: 10.1111/cen.12503
  3. Reznikov AG. The point of view of pathophysiologist-endocrinologist on the problem of age-related androgen deficiency in men (LOH-syndrome). International journal of endocrinology. 2014;(6): 11–18. EDN: TOBRFN
  4. Tyuzikov IA, Kalinchenko SJ. Androgen deficiency in general medical practice: endocrinology, rational diagnosis and clinical ‘masks’. Medical alphabet. 2012;3(15):59–68. EDN: PWXLVR
  5. Ohlsson C, Barrett-Connor E, Bhasin S, et al. High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. The MrOS (Osteoporotic Fractures in Men) study in Sweden. J Am Coll Cardiol. 2011;58(16):1674–1681. doi: 10.1016/j.jacc.2011.07.019
  6. Muraleedharan V, Marsh H, Kapoor D, et al. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol. 2013;169(6):725–733. doi: 10.1530/EJE-13-0321
  7. Decaroli MC, Vincentisab SD, Rochiraab V. Aging and sex hormones in males. Vitam Horm. 2021;115:333–366. doi: 10.1016/bs.vh.2020.12.014
  8. Chiba K, Fujisawa M. LOH (late-onset hypogonadism) syndrome. Nihon Rinsho. 2017;75(4):588–592.
  9. Efremov EA, Krasnyak SS. Potential risks of testostetone replacement therapy. Experimental and clinical urology. 2017;(1): 90–96. EDN: ZEHPGR
  10. Liu Y-J, Shen X-B, Yu N, et al. Prevalence of late hypogonadism among middle-aged and elderly men in China: results of a national survey. Asian J Androl. 2021;23(2):170–177. doi: 10.4103/aja.aja_59_20
  11. Amano T. Role of androgen in the elderly. Clinical androgen replacement therapy for late-onset hypogonadism. Clin Calcium. 2013;23(8):1179–1184.
  12. Kogan MI, Vorobiev SV, Khripun IA, et al. Testosterone: from sexuality to metabolic control. Rostov-on-Don: Phoenix; 2017. 239 p. (In Russ.)
  13. Stanworth RD, Kapoor D, Channer KS, Jones TH. Statin therapy is associated with lower total but not bioavailable or free testosterone in men with type 2 diabetes. Diabetes Care. 2009;32(4):541–546. doi: 10.2337/dc08-1183
  14. Corona G, Boddi V, Balercia G, et al. The effect of statin therapy on testosterone levels in subjects consulting for erectile dysfunction. J Sex Med. 2010;7(4–1):1547–1556. doi: 10.1111/j.1743-6109.2009.01698
  15. de Keyser CE, de Lima FV, de Jong FH, et al. Use of statins is associated with lower serum total and non-sex hormone-binding globulin-bound testosterone levels in male participants of the Rotterdam Study. Eur J Endocrinol. 2015;173(2):155–165. doi: 10.1530/EJE-14-1061
  16. Oluleye OW, Kronmal RA, Folsom AR, et al. Association between statin use and sex hormone in the multi-ethnic study of atherosclerosis cohort. J Clin Endocrinol Metab. 2019;104(10):4600–4606. doi: 10.1210/jc.2019-00530
  17. Camici GG, Savarese G, Akhmedov A, Luscher TF. Molecular mechanism of endothelial and vascular aging: implications for cardiovascular disease. Eur Heart J. 2015;36(48):3392–33403. doi: 10.1093/eurheartj/ehv87
  18. Vigen R, O’Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310(17):1829–1836. doi: 10.1001/jama.2013.280386
  19. Khaw K-T, Dowsett M, Folkerd E, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk). Prospective population study. Circulation. 2007;116(23):2694–2701. doi: 10.1161/circulationaha.107.719005
  20. Lebedeva NB, Gofman VV. Age-related hypogonadism and cardiovascular disease risk. Fundamental and clinical medicine. 2020;5(2): 60–66. EDN: ZVEVIH doi: 10.23946/2500-0764-2020-5-2-60-66
  21. Shustov SB, Kitsyshin VP, Frolov DS, Makarova AV. Late-onset hypogonadism effects on coronary heart disease. Herald of North-Western state medical university named after I.I. Mechnikov. 2017;(1):28–33. EDN: YLDZLP
  22. Vlachopoulos C, Pietri P, Ioakeimidis N, et al. Inverse association of total testosterone with central haemodynamics and left ventricular mass in hypertensive men. Atherosclerosis. 2016;250(1):57–62. doi: 10.1016/j.atherosclerosis.2016.04.018
  23. Chrysant SG, Chrysant GS. Cardiovascular benefits and risks of testosterone replacement therapy in older men with low testosterone. Hosp Pract Rev. 2018;46(2):47–55. doi: 10.1080/21548331.2018.1445405
  24. Yes BB, Anawalt BD. Why is understanding the relationship of testosterone with cardiovascular risk so important? Asian J Androl. 2018;20(2):107–108. doi: 10.4103/aja.aja_71_17
  25. English KM, Jones RD, Jones TH, et al. Testosterone acts as a coronary vasodilator by a calcium antagonistic action. J Endocrinol Invest. 2002;25(5):455–458. doi: 10.1007/bf03344037
  26. Yeap BB, Chubb SAP, Hyde Z, et al. Lower serum testosterone is independently associated with insulin resistance in non-diabetic older men: the health in men study. Eur J Endocrinol. 2009;161(4):591–598. doi: 10.1530/EJE-09-0348
  27. Sesti F, Pofi R, Minnetti M, et al. Late-onset hypogonadism: Reductio ad absurdum of the cardiovascular risk-benefit of testosterone replacement therapy. Andrology. 2020;8(6):1614–1627. doi: 10.1111/andr.12876
  28. Kashtalap VV, Hryachkova ON, Barbarash OL. “New” pathological continuum: a hypogonadism, an osteoporosis and the calcinating atherosclerosis. General factors of formation and progression. Ateroscleroz. 2016;12(4):68–78. EDN: XQOKPB
  29. Kravchenko AYa. Androgen deficiency and ischaemic heart disease in men. Palliative medicine and rehabilitation. 2007;(4):49–54. EDN: MQCLHL (In Russ.)
  30. Murashov IS, Volkov AM, Kliver EE, et al. Immunohistochemical evaluation of forming unstable atherosclerotic plaque. Bulletin of forensic medicine. 2017;6(2):36–40. EDN: ZAOYGZ
  31. Gulevskaya TS, Morgunov VA, Anufriev PL. Structure of atherosclerotic plaques of the carotid sinus and cerebral circulation disorders. Annals of clinical and experimental neurology. 2010;4(1):13–19. EDN: LAMGGJ (In Russ.)
  32. Mirkhalikova DI. Morphological aspects of atherosclerosis. Medicus. 2021;(2):30–34.
  33. Melnik M, Shilov A, Osiya A, Gryaznov D. Statins in primary and secondary prevention of cardiovascular diseases. The Doctor. 2010;(11):21–26. EDN: MXFQNZ
  34. Drapkina O, Palatklna L, Zyatenkova E. Pleiotropic effects of statins. Action on vascular rigidity. The Doctor. 2012;(9):5–9. EDN: KOPZMN
  35. Baspınar O, Bayram F, Korkmaz S, et al. The effects of statin treatment on adrenal and sexual function and nitric oxide levels in hypercholesterolemic male patients treated with a statin. J Clin Lipidol. 2016;10(6):1452–1461. doi: 10.1016/j.jacl.2016.09.004
  36. Karpov YuA. New guidelines for correction of lipid metabolism disorders: the role of combined lipid-lowering therapy. Atmosphere. Cardiology news. 2020;(2):3–10. EDN: EYIUAG doi: 10.24411/2076-4189-2020-12232
  37. Chernukha GE, Nemova YuI, Blinova IV. Role of statins in the correction of endocrine and metabolic disorders in polycystic ovary syndrome. Obstetrics and gynecology. 2012;(5):38–43. EDN: PIICZV
  38. Chou C-Y, Yang Y-F, Chou Y-J, et al. Statin use and incident erectile dysfunction — A nationwide propensity-matched cohort study in Taiwan. Int J Cardiol. 2016;202:883–888. doi: 10.1016/j.ijcard.2015.10.012
  39. Iakovenko EI, Mamedov MN. Effects of statin therapy on erectile function. Russian journal of preventive medicine and public health. 2012;15(3):29–33. EDN: PEKBHR
  40. Trivedi D, Wellsted DM, Collard JB, Kirby M. Simvastatin improves the sexual health-related quality of life in men aged 40 years and over with erectile dysfunction: additional data from the erectile dysfunction and statin trial. BMC Urology. 2014;14(1):24. doi: 10.1186/1471-2490-14-24
  41. Kostis JB, Dobrzynski JM. The effect of statins on erectile dysfunction: a meta-analysis of randomized trials. J Sex Med. 2014;11(7):1626–1635. doi: 10.1111/jsm.12521
  42. Cai X, Tian Y, Wu T, et al. The role of statins in erectile dysfunction: a systematic review and meta-analysis. Asian J Androl. 2014;16(3):461–466. doi: 10.4103/1008-682X.123678
  43. Ference BA, Cannon CP, Landmesser U, et al. Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration. Eur Heart J. 2018;39(27):2540–2545. doi: 10.1093/eurheartj/ehx450
  44. Navarese EP, Buffon A, Andreotti F, et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Epub. 2013;111(8):1123–1153. doi: 10.1016/j.amjcard.2012.12.037
  45. Omolaoye TS, Halabi MO, Mubarak M, et al. Statins and male fertility: is there a cause for concern? Toxics. 2022;10(10):627. doi: 10.3390/toxics10100627
  46. Kocum TH, Ozcan TI, Gen R, et al. Does atorvastatin affect androgen levels in men in the era of very-low LDL targeting therapy? Exp Clin Endocrinol Diabetes. 2009;117(2):60–63. doi: 10.1055/s-2008-1077066
  47. Grundy SM, Stone NJ, Bailey AL, et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association task forceon clinical practice guidelines. J Am Coll Cardiol. 2019;73(24):e285–e350. doi: 10.1016/j.jacc.2018.11.003
  48. Mędraś M, Kubicka E, Jóźkow P, et al. Treatment with statins and testosterone levels in men. Endokrynol Pol. 2014;65(6):464–472. doi: 10.5603/EP.2014.0064
  49. Shawish MI, Bagheri B, Musini VM, et al. Effect of atorvastatin on testosterone levels. Cochrane Database Syst Rev. 2021;1(1):14651858. doi: 10.1002/14651858
  50. Mastalir ET, Carvalhal GF, Portal VL. The effect of simvastatin in penile erection: a randomized, double-blind, placebo-controlled clinical trial (Simvastatin treatment for erectile dysfunction-STED TRIAL). Int J Impot Res. 2011;23(6):242–248. doi: 10.1038/ijir.2011.33
  51. Trivedi D, Kirby M, Norman F, et al. Can simvastatin improve erectile function and health-related quality of life in men aged >40 years with erectile dysfunction? Rationale and design of the Erectile Dysfunction and Statins (EDS) Trial [ISRCTN66772971](1). BJU Int. 2011;108(11):1850–1854. doi: 10.1111/j.1464-410X.2011.10122.x
  52. Davis R, Reveles KR, Ali SK, et al. Statins and male sexual health: a retrospective cohort analysis. J Sex Med. 2015;12(1): 158–167. doi: 10.1111/jsm.12745
  53. Elgendy AY, Elgendy IY, Mahmoud AN, et al. Statin use in men and new onset of erectile dysfunction: a systematic review and meta-analysis. Am J Med. 2018;131(4):387–394. doi: 10.1016/j.amjmed.2017.10.043
  54. Zhang X, Li J, Zhou X, et al. Simvastatin decreases sex hormone levels in male rats. Endocr Pract. 2017;23(2):175–181. doi: 10.4158/EP161274.OR
  55. Leite GAA, Sanabria M, Cavariani MM, et al. Lowe sperm quality and testicular and epididymal structural impairment in adult rats exposed to rosuvastatin during prepuberty. J Appl Toxicol. 2018;38(6):914–929. doi: 10.1002/jat.3599
  56. Buyanova SV, Osochuk SS. Effect of statins on blood hormonal spectrum and cholesterol content in adrenal glands of white laboratory rats. Vitebsk medical journal. 2014;13(1):31–37. EDN: RZATUD (In Russ.)
  57. Klinefelter GR, Laskey JW, Amann RP, et al. Statin drugs markedly inhibit testosterone production by rat Leydig cells in vitro: implications for men. Reprod Toxicol. 2014;45(1):52–60. doi: 10.1016/j.reprotox.2013.12.010
  58. Morelli A, Chavalmane AK, Filippi S, et al. Atorvastatin ameliorates sildenafil-induced penile erections in experimental diabetes by inhibiting diabetes-induced RhoA/Rho-kinase signaling hyperactivation. J Sex Med. 2009;6(1):91–106. doi: 10.1111/j.1743-6109.2008.01057.x
  59. Bruckert E, Giral P, Heshmati HM, Turpin G. Men treated with hypolipidaemic drugs complain more frequently of erectile dysfunction. J Clin Pharm Ther. 1996;21(2):89–94. doi: 10.1111/j.1365-2710.1996.tb00006.x
  60. Hall SA, Kupelian V, Rosen RC, et al. Is hyperlipidemia or its treatment associated with erectile dysfunction?: Results from the Boston Area Community Health (BACH) Survey. J Sex Med. 2009;6(5): 1402–1413. doi: 10.1111/j.1743-6109.2008.01207.x
  61. Yakovenko EI, Evdakimova AA, Toguzova ZA, et al. Dose-dependent effect of atorvastatin on erectile function and androgen status in men with high cardiovascular risk. Kardiologiia. 2014;(2):37–42. EDN: RYRGFP doi: 10.18565/cardio.2014.2.37-42
  62. Do C, Huyghe E, Lapeyre-Mestre M, et al. Statins and erectile dysfunction: results of a case/non-case study using the French Pharmacovigilance System Database. Drug Saf. 2009;32(7):591–597. doi: 10.2165/00002018-200932070-00005
  63. Hsieh CJ, Huang B. Rosuvastatin decreases testosterone levels but not sexual function in men with type 2 diabetes. Diabetes Res Clin Pract. 2016;120(1):81–88. doi: 10.1016/j.diabres.2016.07.026
  64. Böhm M, Herrmann W, Wassmann S, et al. Does statin therapy influence steroid hormone synthesis? Z Kardiol. 2004;93(1):43–48. doi: 10.1007/s00392-004-1003-2
  65. Schooling CM, Au Yeung SL, Freeman G, Cowling BJ. The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials. BMC Med. 2013;28(1):57. doi: 10.1186/1741-7015-11-57
  66. Ose L, Davidson MH, Stein EA, et al. Lipid-altering efficacy and safety of simvastatin 80 mg/day: Long-term experience in a large group of patients with hypercholesterolernia. Clin Cardiol. 2000;23(1):39–46. doi: 10.1002/clc.4960230108
  67. Dobs AS, Schrott H, Davidson MH, et al. Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia. Metabolism. 2000;49(9):1234–1238. doi: 10.1053/meta.2000.7716a
  68. Smals AGH, Weusten JJAM, Benraad TJ. The HMG-CoA reductase inhibitor simvastatin suppresses human testicular testosterone synthesis in vitro by a selective inhibitory effect on 17-ketosteroid-oxidoreductase enzyme activity. J Steroid Biochem Mol Biol. 1991;38(4):465–473. doi: 10.1016/0960-0760(91)90333-Z
  69. Hall SA, Page ST, Travison TG, et al. Do statins affect androgen levels in men? Results from the Boston area community health survey. Cancer Epidemiol Biomarkers Prev. 2007;16(8): 1587–1594. doi: 10.1158/1055-9965.EPI-07-0306
  70. Keihani S, Martin C, Craig JR, et al. Semen parameters are unaffected by statin use in men evaluated for infertility. Andrologia. 2018;50(5):e12995. doi: 10.1111/and.12995
  71. Azzarito C, Boiardi L, Vergoni W, et al. Testicular function in hypercholesterolemic male patients during prolonged simvastatin treatment. Horm Metab Res. 1996;28(4):193–198. doi: 10.1055/s-2007-979159
  72. Dobs AS, Sarma PS, Schteingart D. Long-term endocrine function in hypercholesterolemic patients treated with pravastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Metabolism. 1993;42(9):1146–1198. doi: 10.1016/0026-0495(93)90272-p
  73. Tada Y, Kitaya K, Hayashi T, et al. Transient azoospermia following rosuvastatin medication for hypercholesterolemia. Clin Exp Obstet Gynecol. 2015;42(4):545–551. doi: 10.12891/ceog1925.2015
  74. Sniderman AD, Thanassoulis G. Do statins lower testosterone and does it matter? BMC Med. 2013;11:58. doi: 10.1186/1741-7015-11-58

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Eco-Vector, 2024

Creative Commons License
此作品已接受知识共享署名-非商业性使用-禁止演绎 4.0国际许可协议的许可。
 


Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».